Atlas Trials

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Clinical trial NCT02210871 · COMPLETED

Trial details

NCT number
NCT02210871
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
DiabetesDiabetes Mellitus, Type 2Hepatic Impaired
Start date
2014-08-07
Primary completion
2015-06-03
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.